Video
Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC
Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Eleni Efstathiou, MD, an associate professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide (Erleada) and abiraterone acetate (Zytiga) plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
The phase 3 trial, which was presented during the 2021 Genitourinary Cancers Symposium, was designed to examine radiographic progression free survival (rPFS) between the 2 treatment arms, directly after patients became castration resistant, Efstathiou explains. Secondary end points included overall survival and time to initiation of cytotoxic chemotherapy, as well as exploratory measures of biomarkers and patient-reported outcomes, Efstathiou adds.
Results from the final analysis showed a difference in rPFS of more than 7 months between the 2 arms, which has not been previously observed in this patient population, Efstathiou concludes.
